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Background: With the advent of Next Generation Sequencing (NGS) technologies, the ability to generate large
amounts of sequence data has revolutionized the genomics field. Most RNA viruses have relatively small genomes
in comparison to other organisms and as such, would appear to be an obvious success story for the use of NGS
technologies. However, due to the relatively low abundance of viral RNA in relation to host RNA, RNA viruses have
proved relatively difficult to sequence using NGS technologies. Here we detail a simple, robust methodology,
without the use of ultra-centrifugation, filtration or viral enrichment protocols, to prepare RNA from diagnostic
clinical tissue samples, cell monolayers and tissue culture supernatant, for subsequent sequencing on the Roche
454 platform.
Results: As representative RNA viruses, full genome sequence was successfully obtained from known lyssaviruses
belonging to recognized species and a novel lyssavirus species using these protocols and assembling the reads
using de novo algorithms. Furthermore, genome sequences were generated from considerably less than 200 ng
RNA, indicating that manufacturers’ minimum template guidance is conservative. In addition to obtaining genome
consensus sequence, a high proportion of SNPs (Single Nucleotide Polymorphisms) were identified in the majority
of samples analyzed.
Conclusions: The approaches reported clearly facilitate successful full genome lyssavirus sequencing and can be
universally applied to discovering and obtaining consensus genome sequences of RNA viruses from a variety of
sources.
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RNA viruses have small, simple genomes, which have a
high level of diversity, due to the low-fidelity viral poly-
merase used for replication. Traditionally, due to their
small genomes, ‘genome-walking’ was used to obtain a
reference sequence, from which primer pairs can be
designed for down-stream use on similar viruses [1-6].
However, this methodology can take a large amount of
time, effort and expense, and be cumbersome, not least
because of the variation within virus species, which re-
sults in the need to redesign primer pairs and frequent* Correspondence: Lorraine.McElhinney@ahvla.gsi.gov.uk
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reproduction in any medium, provided the orre-optimization of conditions. In addition to these
optimization issues, every novel virus discovered will re-
quire ‘genome walking’. Moreover, the introduction of
PCR errors using Sanger-based sequencing is problem-
atic, particularly when sequencing from cloned DNA.
The use of high-fidelity enzymes and sequencing PCR
products directly can overcome this issue in part, but er-
rors occurring early in the amplification process will be
sequenced incorrectly [7]. These problems can be avoided
by utilizing Next Generation Sequencing (NGS), a high-
throughput sequencing methodology which generates mil-
lions of sequences simultaneously from one sample [8].
Multiple platforms are available, the two commonly used
are Roche 454 pyrosequencing (454 Life Science) and
Illumina (Solexa) [9]. These platforms were initially devel-
oped and applied to mammalian and bacterial genomes,
where Sanger methods were prohibitively expensive.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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traditional PCR/Sanger methods, the virology field has had
less necessity to embrace this new technology. The current
NGS assays are optimized for large bacterial or mammalian
genomes, where nucleic acid is in abundance and obtaining
the hundreds of nanograms of nucleic acid required, is
relatively simple. Due to the low percentage of viral RNA
in relation to host RNA in any given sample, obtaining the
quantity of viral RNA required by the protocols can be
problematic.
The advantages of NGS technologies in virology are nu-
merous, and its use is becoming more commonplace [10],
particularly to detect and characterize pathogens without
prior knowledge of their existence, or in association with
the sequelae/disease outcome, in primary or cultured ma-
terial, without the requirement of specific primers [11,12].
Often however, the virus is at such low abundance in these
samples that only one or two reads can be obtained, or at
best, a number of unlinked contiguous sequences (contigs),
for which traditional Sanger protocols are employed to
complete the genome [13,14]. Conversely, known positive
samples have been ‘deep sequenced’ using NGS tech-
nologies, for a plethora of uses including determining
viral heterogeneity, or the effect of the immune system
or pharmaceutical drugs on viruses [15-19]. These deep
sequencing methodologies employ the use of viral PCR
amplicons to obtain a depth of coverage sufficient to de-
tect variants which occur down to 0.1% frequency. Be-
tween these two approaches, a methodology to obtain
full genome sequences directly from known positive
clinical specimens or cultured material, without the use
of amplicons, viral enrichment or virus concentration is
still lacking. To this end, we describe a broadly applic-
able approach to obtaining full genome sequences from
clinical or cultured samples, which we have successfully
applied to lyssavirus infected samples.
Lyssaviruses (family Rhabdoviridae) have negative-sense,
single-stranded RNA genomes approximately 12 kb long.
Traditionally, partial gene sequence (usually the N-gene)
was utilized for viral speciation and phylogenetic analysis.
However, limitations on the information obtained from
these partial sequences and a requirement to use full gen-
ome sequence as part of the ICTV (International Commit-
tee for Taxonomy of Viruses) criteria to propose new
lyssavirus species, in combination with recent advances in
high-throughput sequencing, have resulted in an increase
of full genome sequences available on Genbank. From the
submission of the first full length lyssavirus genome se-
quence of RABV (prototype) in 1988 [20] to the completion
of representative genomes from each of the established
twelve lyssavirus species (RABV, LBV, MOKV, DUVV,
EBLV-1, EBLV-2 and ABLV, ARAV, KHUV, IRKV, WCBV
and SHIBV) in 2010, the commonly used methodology for
obtaining the genomes was relatively unchanged, utilizingreverse transcription then either cloning the cDNA directly,
or cloning amplified PCR products, and Sanger sequencing
[2,5]. Of the most recently described lyssavirus species,
BBLV [21] and IKOV [22], only the IKOV characterization
employed NGS technologies to obtain the full genome se-
quence, pioneering the way forward to obtaining genome
sequences without the requirement to design multiple
primers necessary for genome walking.
This study describes the optimization of protocols, re-
quired for a variety of starting material, describing a robust,
simple, reliable methodology to obtain full genome se-
quences from original clinical material and cultured sam-
ples, both from the cell monolayer and the supernatant.
Furthermore, we investigate the SNPs (Single Nucleotide
Polymorphisms) observed in the sequences obtained.
Results
Optimization of the extraction protocol for tissue samples
Two different extraction methodologies were compared
to investigate the suitability of the RNA obtained. Three
brain tissue samples (RV2772, RV2627 and RV2516)
were extracted, using the same amount of starting ma-
terial, either by TRIzol® extraction followed by isopropa-
nol precipitation, or RNeasy® plus mini kit (see Table 1
for isolate details and Table 2 for details of extraction).
Genomic DNA depletion was carried out on-column, ei-
ther as a separate step for the TRIzol® extracted RNA, or
as part of the RNA extraction procedure, using the
RNeasy® plus mini kit. The RNA concentration from the
RNeasy® kit extracted samples were significantly lower
than the TRIzol® extracted equivalents (Table 2). The re-
quired 200 ng RNA (10 ng/μl), was not achieved for the
RNeasy® kit samples, or indeed for the RV2772 TRIzol®
extracted sample. For these samples the maximum RNA
(20 μl) was used with varying success.
The number of total reads and viral reads obtained for
the RNeasy® kit samples were lower in comparison to
the TRIzol® extracted RNA, most likely due to the differ-
ence in total RNA available for these samples. On the
whole, viral RNA was not enriched by the RNeasy® kit,
as the percentage of viral reads was less for RV2627 and
RV2516, although for RV2772 there was a slight increase
in viral specific reads. Without exception, none of the
RNeasy® kit extracted sample reads were sufficient to ob-
tain a single consensus sequence, due to the low number
of viral reads obtained. Furthermore, de novo assembly
on two of the three samples (RV2516 and RV2627) failed
to align viral reads into contigs for further analysis
resulting in only host contigs being identified (Table 2).
Analysis of depletion methodology
Regardless of the originating sample (brain tissue, cell
monolayer, tissue culture supernatant) the concentration
of the TRIzol® extracted RNA after gDNA depletion was






























































* Published after sequence was obtained prior to this publication.
† Sequence confirmed by Sanger sequencing from the bat brain material.
#Both brain and TCSN were sequenced. For analysis see Table 2.
- Data not available.
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(Table 2). The largest reduction was for RV2772 where
RNA at 1,833 ng/μl was depleted to 3.27 ng/μl (600-fold
reduction) after removal of genomic DNA. Interestingly,
this sample was part of a cohort of samples that were
highly degraded upon receipt, therefore the majority of
RNA had already been degraded. Otherwise a reduction
of concentration between 3-fold and 100-fold was ob-
served (Table 2). The subsequent depletion of rRNA
resulted in a more conservative fold change of concen-
tration between 30-fold (RV2417) and 2-fold (RV2772
and RV2508).
We investigated the requirement to deplete gDNA and
rRNA in cultured viral samples after RNA extraction,since the amount of cellular material would be minimal
in these supernatant preparations. Comparison at the
RiboGreen stage determined that RV20 and RV1787 de-
pleted samples are 45-fold and 10-fold less than the
RV20 and RV1787 non-depleted RNA samples respect-
ively. Indeed, for RV20 the total amount of RNA was
too low to obtain 200 ng RNA for fragmentation. The
virus titer of RV1787 and RV20 has been calculated pre-
viously [23,24] with RV1787 (EBLV-2) approximately 1
log lower than RV20, therefore the difference in the per-
centage of viral reads is likely to be a reflection of this.
Despite the marked difference between the percentage
of viral reads of RV20 and RV1787, the difference within
samples regarding whether the RNA was depleted or
not, is not so obvious. Indeed, for both samples, the
RNA sequenced directly without depletion provided
more viral-specific reads.
The success of the methodology for both tissue mater-
ial and cell cultured material, particularly the ability to
detect viral sequence after de novo assembly, is illus-
trated in Table 2. Apart from the column-extracted sam-
ples, all sequences obtained were sufficient to obtain
viral specific reads either as a single contig, or a number
of contigs, which subsequently can be identified by a
BLAST search.
Depth of coverage analysis
The depth of viral read coverage of samples from which
a single genome contig was obtained was investigated
(Figure 1). Brain tissue sample read depths varied from
RV50, total viral reads 293, maximum read depth 16,
and average read depth of 8.6; to RV437, total viral reads
1,489, maximum read depth 103, and average read depth
of 44 (Figure 1a, Tables 2 and 3). RV61 did have a higher
number of viral reads, but from two runs, therefore not
directly comparable. Read depths from cell cultured viral
samples were higher, with average read depths of 31
(RV20 depleted), 125 (RV20) and 65 (RV2324 cell pellet)
and maximum read depths of 69 (RV20 depleted), 228
(RV20) and 272 (RV2324 cell pellet) (Figure 1b, Table 3).
Viral heterogeneity analysis
Due to the processes involved, each read is obtained
from a single cDNA strand, and therefore where mul-
tiple reads cover a region viral heterogeneity can be
detected within the reads indicating the presence of a
heterologous viral population. Although this method-
ology is not optimized for investigation of low level viral
populations, which would require viral read depths of
over 10,000, it is still possible to observe dominant or
high level single nucleotide polymorphisms (SNPs). Even
with this dataset, we were able to observe minimum
SNPs (equating to one read with a SNP) at 1% of the
population in cultured material, and 3% in brain tissue
Table 2 Details of brain and BHK cultured samples, relating to the extraction method used and RNA concentration






























RV437 mouse TRIzol® 5,404.4 410.77 121.77 282,370 1,489 0.53 Yesa Yes
RV61 mouse TRIzol® 3,362.8 ND 58.9 191,508# 1,810 0.95 Yesc Yes
RV2417 Dog TRIzol® 5,431.3 1799.21 57.78 96,014 1,488 1.55 Yesb Yes
RV2508 African
civet^
TRIzol® 6,537.4 66.55 28.18 139,841 626 0.45 Yesa Yes
RV2627 Cow TRIzol® 2,385.8 111.81 26.60 11,470 682 5.95 Yes Yes
RNeasy
mini
N/A 4.99 0.95 239 2 0.84 No No
RV2516 Cow TRIzol® 1,891.2 45.84 11.09 154,068# 550 0.36 Yesa Yes
RNeasy
mini
N/A 11.12 2.14 7,991 17 0.21 No No
RV50 mouse TRIzol® 2,186.2 18.76 7.64 76,568 293 0.38 Yes Yes
RV2772 Dog TRIzol® 1,833.9 3.27 1.50 305,110 391 0.13 Yes Yes
RNeasy
mini
N/A 7.19 1.08 48,849 180 0.37 No Yes
BHK cultured virus samples





TRIzol® LS 3,732.6 2.8 0.52 2,537 1,054 41.55 Yes Yes





TRIzol® LS 4,603 37.87 11.56 8,162 53 0.65 No Yes





TRIzol® LS 129.44 ND 11.45 14,587# 223 1.529 No* Yes
RV2508 no
cells
127.05 ND 0.46 326 42 12.88 No* Yes
RV2508
high titre
112.5 ND 1.31 1,132 12 1.06 No* Yes
TCSN tissue culture supernatant; N/A – Not Applicable as DNAse treatment is incorporated in the RNA extraction protocol, therefore no concentration before
gDNA depletion is available; ND - Not Done as gDNA was not depleted from these samples; 1This column contains the RNA concentration after rRNA depletion for
all samples, except RV20, RV1787 and RV2508 TCSN where no rRNA depletion was undertaken. †brain either from host, or from one passage in a mouse,
*combining these reads resulted in a single genome contig; # combined results from two 454 runs of same library; ^ Stored in RNAlater; a 3’UTR not represented;
b 5’UTR not represented; c 3’ and 5’ UTR not represented.
Brain tissue samples ordered by concentration after the depletion process. Where rRNA depletion was not undertaken (RV20, RV1787 and RV2508 TCSN), the
concentration values in the Ribogreen column are directly comparable to the RNA extraction concentration.
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more SNPs than tissue samples, where some tissue sam-
ples (RV2417, RV2627, RV2516) had no detectable SNPs
(Table 3). Of the 28 nucleotide substitutions observed,
22 (79%) were conservative (pyrimidine to pyrimidine or
purine to purine). Substitutions were identified through-
out the genome, although only one was identified outside
of a coding region (RV20 at position 3143 in the M-G un-
translated region). At the amino acid level, 8 (29%) were
synonymous substitutions resulting in no amino acid
change (Table 3). Two stop codon substitutions wereidentified in this dataset, both in the RV20 tissue culture
supernatant samples, and both at a low level (2%) equating
to a single read (Table 3). Furthermore, one of these (N-
gene position 276) had two reads which differed from the
consensus, one encoding a stop codon, resulting in a trun-
cated Nucleoprotein transcript, the other a synonymous
change (Tyr/Tyr92) (Figure 2a).
RV61, an Arctic-like RABV, had one SNP detected in
the 454 read data at genome position 3503 (Figure 2b).
This SNP is located in the glycoprotein gene resulting























































































Figure 1 Depth of sequence obtained from (a) infected brain samples and (b) from cultured samples.
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http://www.biomedcentral.com/1471-2164/14/444a frequency of 18%. Analysis of currently available
lyssavirus glycoprotein sequences, indicates this resi-
due is Isoleucine in the majority of lyssavirus species.
RV61 glycoprotein sequence is available in Genbank,
deposited separately by two independent laboratories.
No original material is available for analysis and the
published sequences are from passaged viruses. Inter-
estingly, alignments of the published sequences and
the sequence obtained in this study are 100% identical,
apart from this residue, where JQ685981 had Ile70 and
GU936881 had Thr70 (Figure 2b).RV50, a US isolate (isolated from Eptesicus fuscus),
was genome sequenced using Sanger sequencing as
part of a larger dataset [6], providing a unique op-
portunity to analyze the same virus isolate, propa-
gated and sequenced independently. Alignments of
the published RV50 genome (JQ685956) and the con-
sensus sequence obtained in this study showed 100%
identity. However, the 454 data identified a SNP at
genome position 11,349 (L-gene), resulting in a non-
synonymous coding change at residue 1982 resulting
in conservative substitution Asn/Asp1982 (Figure 2c).
























RV437 44 103 60 8 2768 M (275) T C Leu Ser 92
63 3 2781 M (288) T C Val Val 96
55 51 3049 M (556) T C Leu Phe 186
28 18 4403 G (1090) T C Leu Leu 364
28 7 7855 L (2451) C T Asn Asn 817
RV2417 35.5 81 NA
RV61 53.2 165 34 18 3503 G (209) C T Ile Thr 70
RV2508 17 53 17 23 9523 L (4128) A G Ser Ser 1376
RV2627 17.7 46 NA
RV2516 16.5 43 NA
RV50 8.6 16 11 27 11349 L (5944) C G Asn Asp 1982
RV2772 14.5 31 13 38 1293 N (1223) A G Lys Arg 408
22 5 8179 L (2771) T A Phe Tyr 924
Cultured virus samples
RV2324 65 272 47 11 3490 G (175) G A Glu Lys 59
47 21 3491 G (176) A G Glu Gly 59
42 31 3711 G (396) C A His Gln 132
44 25 4103 G (788) A G Gln Arg 263
36 11 8376 L (2967) C T Asp Asp 989
RV1787 combined 4.3 11 4 25 2679 M (170) G A Gly Glu 57
RV20 combined 156 277 107 2 346 N (276) C A/T Tyr */Tyr 92
87 2 1621 P (105) T C Ser Ser 35
81 2 1669 P (153) G A Glu Glu 51
77 3 1710 P (194) A T Gln Leu 65
93 39 3143 M-G (NA) C T NA NA NA
103 2 3671 G (356) G A Trp * 119
96 2 4403 G (1087) T C Cys Arg 363
94 37 4584 G (1268) T C Met Thr 423
95 2 6217 L (766) T C Ser Pro 256
134 1 7910 L (2459) T C Ile Thr 820
107 2 8244 L (2793) C A Ser Arg 931
106 2 8473 L (3022) A G Thr Ala 1008
NA = not applicable as no SNPs were observed. * stop codon.
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27% (Table 3).
RV2508 was sequenced both from the host brain tissue
directly and from cell culture supernatant after 6 passages
in BHK cells. Only one SNP was observed at position 9523
(L-gene) a synonymous coding change A/G9523. Of the 17
original brain tissue reads covering this region, 23% were
G9523, whereas the tissue culture supernatant sample reads
(n = 2) only had G9523. To investigate this variation further,
specific primers were designed to amplify this region from
the original brain sample and the passaged TCSN. Theoriginal brain material PCR amplicon had a read depth of
3783 reads, 18.4% G9523 and 81.6% A9523. The TCSN PCR
amplicon had a read depth of 3280 reads, 97.5% G9523 and
2.5% A9523, confirming the consensus sequence data, but
indicating the A variant is still present after 6 passages, just
at a much lower level. This deep sequence analysis is a use-
ful tool to investigate certain SNPs of interest indicated
from the consensus data.
RV437, a raccoon-dog RABV from Estonia, had good
coverage across the genome (average read depth 44, max-
imum read depth 103) and also had the most SNPs
Figure 2 Alignment of 454 reads for (a) RV20 consensus sequence and the reads with variations, (b) RV61 consensus sequence and
published RV61 glycoprotein gene sequences and (c) RV50 published genome sequence; * indicating single nucleotide polymorphisms
which are detailed at the top of each figure.
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ome, 5 SNPs were detected, 3 within the M-gene (2 of
which resulted in amino acid changes – Leu/Ser92 and Leu/
Phe186) and one synonymous change at genome position
2781. The remaining two were both silent, one in the glyco-
protein gene (genome position 4403) and the other in the
L-gene (genome position 7855) (Table 3).
Although a full genome contig was not obtained for
RV1787, 6 contigs covering approximately 90% of the gen-
ome were generated. Full genome sequence had previously
been generated using overlapping PCR products and
Sanger sequencing [1]. Comparison between the Sanger
and 454 generated sequences revealed 100% match apartfrom a single nucleotide polymorphism (SNP) at genome
position 2679 (residue 57 in the Matrix Protein) which
corresponded to substitution Gly/Glu (Table 3). Published
sequences of all lyssavirus species (including the recently
identified IKOV; [22] have Gly57. The read coverage at this
position was 6 reads, 5 of which contained the Glu57 SNP
and 1 contained the original Gly57, present in the Sanger
sequencing and all other lyssaviruses.
Obtaining genomic termini
The genomic termini sequences from 454 data were
obtained with varying success. The 5′ UTR was usually rep-
resented by reads more often than the 3′ UTR, the reasons
Marston et al. BMC Genomics 2013, 14:444 Page 8 of 12
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assembly failed to incorporate reads which contained the
genomic termini. These reads were only incorporated
after splicing the missing sequence, from a published
similar genomic sequence, to the consensus sequence
deduced from the de novo assembly and subsequently
mapping reads against the spliced reference using GS
mapper. Subsequent to this dataset, in an attempt to in-
crease the population of genomic end viral reads, the
454 sample preparation methodology was modified by
the addition of 1pmol of N165-146 and LRACEF2 at the
hexamer cDNA synthesis stage, to enhance the cDNA
population containing the genomic termini. This modi-
fication was trialed on a genome sample highly related
to RV2772, where the genomic ends were obtained (data
not shown). This simple modification will be used for
future genome sequences.
For samples where the genomic termini were still absent,
RT-PCR was performed on the depleted RNA, using
primers designed against the highly conserved genomic ter-
mini to obtain PCR products which were sequenced directly
using Sanger sequencing. Although this approach resulted
in a genome sequence still lacking the sequencing relating
to the primer sites, for known lyssavirus species isolates this
is acceptable. However, for novel lyssavirus species proto-
types the ends must be deduced either by RACE [1] or
circularization of the RNA, followed by RT-PCR [2]. To this
end IKOV genomic ends were obtained using circularization
of the genomic RNA [22].
Confirming correct sequence and differentiating between
indels/homopolymeric repeats
Whenever possible, consensus sequences where aligned to-
gether with genome sequences from the same lyssavirus
species. Any potential insertions or deletions (indels) were
investigated by analysis of the flowgrams in the GS program
suite. A limitation of pyrosequencing processing of raw data
is runs of homopolymers such as the GAAAAAAA poly A
termination signal found at the end of each lyssavirus gene
sequence (Figure 3a and b). Figure 3 illustrates the discrep-
ancies between individual reads from the same sample in a
homopolymeric run, where the signal strength for each
base is plotted for each read. Detecting the correct signal in
a homopolymer of four or more bases can be problematic,
resulting in incorrect base calling. In general, the more reads
covering the genome the more accurate the resulting con-
sensus sequence (represented by contig00001 in Figure 3a).
Where discrepancies cannot be resolved, or a new virus spe-
cies is being sequenced, confirmation of the correct se-
quence using PCR products spanning the region in question
sequenced using Sanger technologies may be required. In
this dataset, only the proposed new lyssavirus species IKOV
(RV2508) required additional PCR confirmation. Each
intergenic region length and sequence was confirmed byRT-PCR, with 100% concurrence between the 454 consen-
sus sequence and the Sanger sequence derived from PCR
products (data not shown).
Discussion
Our goal was to establish a methodology which enabled
sequencing from brain tissue, and cell cultured samples
without the use of specific viral enhancement, ultracen-
trifugation or filtration to identify novel viruses, or ob-
tain genome sequence for known virus species. It was
important to develop a methodology which would not
require prior knowledge of the virus being extracted and
to use a methodology which is widely used to extract
viral RNA. Instead of enriching for virus specific RNA,
we depleted host genomic DNA and rRNA to increase
the percentage of viral specific RNA in the sample.
There are a large number of RNA extraction methodolo-
gies and kits available which can be broadly divided into
two categories; 1) Phenol/choloform based extraction and
2) column or bead based extraction. We decided to com-
pare TRIzol® as a phenol-based system and RNeasy® plus
mini kit (Qiagen) as a column-based system. In our hands,
the use of spin columns to extract the RNA from tissue, re-
moved the majority of RNA in process, resulting in less than
the 200 ng minimum quantity of total RNA recommended
for fragmentation and more importantly, too few viral reads
were obtained. The RNeasy® plus mini kit (Qiagen) was suc-
cessfully used as part of the depletion protocol after initial
extraction with TRIzol® with good results. In this study, less
than 200 ng of RNA was used for a number of samples, and
depending on the sample type less than 200 ng of RNA can
provide full genome sequence. TRIzol® extracted tissue sam-
ples RV50 (153 ng RNA) and RV2772 (30 ng RNA), not
only obtained sufficient reads to cover the genome, but also
obtained enough depth of coverage to identify SNPs (Tables 2
and 3). Furthermore, for RV20 depleted tissue culture super-
natant only 10 ng of RNA was fragmented, yet 1,054 viral
specific reads were mapped equating to 41% of the total
reads obtained. These observations are important to illustrate
that the methods for library preparation can be further re-
fined for virus sequencing.
The requirement to deplete tissue culture supernatant de-
rived RNA was investigated using two 100 ml supernatant
samples. Half the RNA was subjected to gDNA and rRNA
depletion, whereas the other was not. The additional prepar-
ation time required to deplete the sample was not rewarded
with a significant improvement of either proportion of viral-
specific reads or read depth, therefore 454 sequencing dir-
ectly from a TRIzol® extracted RNA is the simplest, yet most
effective way to obtain viral genome sequence from PEG
precipitated tissue culture supernatant samples. However, it
is not always possible, or practical to culture viruses in vitro.
Furthermore, any passaging of viruses in a cell culture




Figure 3 Typical variation of the reads over a homopolymeric repeat at the termination signal of the M-gene displayed as (a) an
alignment of individual 454 reads with the consensus sequence (contig00001) and a reference sequence (RV437) and (b) a flowgram
with reference sequence (RV437, top panel), read G3FY5P04JF0R0 (middle panel) and the difference between the reference sequence
and read (bottom panel).
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tain virus at a high enough titer to harvest, will alter
the population of virus being sequenced. Indeed, the
number of SNPs observed in the cell cultured RNA
preparations were greater than the tissue extracted
samples (Table 3). Furthermore, the number of non-
conservative substitutions observed (both nucleotide
and amino acid) was significantly more in the cultured
samples, including the presence of stop codons
(Table 3). The RV2508 synonymous SNPs identified be-
tween the brain material and the TCSN passaged 6
times in BHK was investigated by designing specific
primers to amplify across the SNP from both the ori-
ginal and cultured virus samples. ‘Deep sequencing’ ofthis amplicon determined that the dominant viral
population changed from G9523 to A9523 after 6 pas-
sages, and although no A9523 SNP reads were observed
in the TCSN consensus sequencing they were still
present in the population, just at a low level (2.5%). Al-
though for this example there is no functional rele-
vance for the variation, this approach is useful to
determine high proportion SNP changes within pas-
saged virus samples using consensus sequencing which
can then be targeted directly by deep sequencing the
relevant genomic regions, rather than deep sequencing
the entire genome.
The genomic termini are often under-represented in
the viral reads obtained. It is likely this is due to a variety
Marston et al. BMC Genomics 2013, 14:444 Page 10 of 12
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fore assembly, the assembly parameters in de novo and
mapping programmes as well as biological influences
such as mRNA over-representing the viral RNA popula-
tion relative to genomic RNA and the effect of defective
interfering (DI) particles which are often truncated. The
use of primers situated near the genomic termini during
the cDNA synthesis stages have been shown to improve
the number of termini sequences, but have not com-
pletely resolved the problem.
Sequences generated on the 454 platform, due to the
way the incorporation of bases are detected by the in-
tensity of light emission, inherently have issues with
long homopolymeric repeats. On the whole, a consen-
sus sequence with 10 or more reads, when mapped
using an available genome from the same species, can
be confidently confirmed by checking the flowgram
data. However, novel viruses, or viruses with a limited
number of reads may require additional confirmation
by Sanger sequencing PCR products, which span the re-
gions in question.
Conclusion
The application of this methodology to lyssaviruses
from brain material and cell cultured samples has been
shown to be highly successful. Moreover, we have suc-
cessfully sequenced the majority of a flavivirus and
hantavirus, demonstrating the applicability of the
method to other families of viruses (data not shown).
There is no reason why any cultured virus cannot be
PEG precipitated, extracted and sequenced using the
same methodology. We have shown for both a high
titer virus (RV20) and a low titer virus (RV1787)
100 ml of supernatant is more than enough to obtain
genome sequence, and to begin to investigate the pres-
ence of viral heterogeneity. Further investigations using
5-10 ml of tissue culture supernatant for a number of
other cultured lyssaviruses have proved equally as suc-
cessful (data not shown). Furthermore, extraction from
the cell monolayer (often discarded when clarifying
harvested supernatant) is an excellent source of viral
RNA. The only disadvantage is the potential presence
of non-functional virus variants presumably present in
the cells as partially synthesized viral derivatives. In this
study however, it was virus in the supernatant which
appeared to contain defective virion particles, albeit at
a low level.
The platform used in this study (Roche 454) has been
shown to be reliable and consistent, however, the RNA
can be prepared for any NGS platform. Indeed we have
obtained full genome sequences from a small number
of RNA samples prepared as described here from brain
material on the Illumina platform successfully (data
not shown). The application of NGS sequencing ofviruses has begun a new era of virus discovery and
characterization of novel viruses and will revolutionize




Original clinical specimens, or once passaged mouse brain
samples (Table 1), confirmed positive previously by FAT
(Fluorescent Antibody Test) and by RT-PCR were used.
Cultured viruses were passaged from original brain sam-
ples in Baby Hamster Kidney cells. All in vivo work was
undertaken in BSL3/SAPO4 containment in AHVLA, fol-
lowing independent ethical review and complied with the
Animal Scientific Procedures Act 1986.
PEG precipitation
Concentration of virus in tissue culture supernatant
(TCSN) over 1 ml (specifically RV20 and RV1787) was
achieved using 1 volume of PEG-it (System Biosciences)
to 4 volumes of TCSN and following manufacturer’s in-
structions. Pellets were combined and resuspended in
tissue culture media to a final volume of 1 ml.
RNA extraction
TCSN samples were clarified to remove cell debris by cen-
trifugation at 1,200 rpm for 5 mins and were extracted ei-
ther directly (250 μl) or after PEG precipitation (see above)
using TRIzol® LS following manufacturer’s instructions and
resuspended in 10 μl molecular grade water. All other sam-
ples were extracted using TRIzol® following manufacturer’s
instructions and eluting in 10 μl molecular grade water.
For RNA extraction method comparisons, duplicate sam-
ples were extracted using RNeasy® plus mini kit (Qiagen),
including the DNase treatment (see 2.4).
gDNA depletion
Genomic host DNA was depleted from the extracted RNA
samples using the on-column DNase treatment in RNeasy®
plus mini kit (Qiagen) following manufacturer’s instruc-
tions, eluting in 30 μl molecular grade water.
rRNA depletion
Ribosomal RNA was depleted from the gDNA-depleted
RNA samples using Terminator™ 5′-Phosphate-Dependent
Exonuclease (Epicentre Biotechnologies). The reaction was
performed according to the manufacturer’s instructions,
briefly, 30 μl of RNA was mixed with 3 μl of Buffer A, 0.5 μl
RNAsin® Ribonuclease inhibitor (20–40 U/μl, Promega) and
1 μl Terminator (1 U/μl). The mixture was incubated at
30°C for 60 minutes. Thereafter the samples were subjected
to subsequent round of purification using RNeasy® plus mini
kit (Qiagen), without DNase digestion, following manufac-
turer’s instructions, eluting in 30 μl molecular grade water.
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After extraction and then gDNA depletion, the RNA
was quantified using NanoDrop® spectrophotometer (re-
sults in Table 2). After rRNA depletion the final RNA
sample was quantified using RiboGreen® on a spectro-
photometer before commencing the 454 RNA prepar-
ation protocols. For TCSN samples which did not
undergo depletion, the RNA was diluted to 1000 ng/ul
according to the nanodrop concentration, then quan-
tified using RiboGreen® on a spectrophotometer.
RNA fragmentation, cDNA library amplification
and sequencing
200 ng of RNA was fragmented using divalent cations
(ZnCl2) at 70°C for 30 s. Where less than 200 ng was
available the maximum volume (20 μl) was used. The
fragmented RNA was then purified using RNAclean XP
(Beckman Coulter) magnetic beads and used as tem-
plate for double-stranded cDNA synthesis using ran-
dom hexamers (Roche) and a cDNA Synthesis System
Kit (Roche) according to the manufacturer’s instruc-
tions. To improve the population of viral reads at the
genomic termini, two panlyssavirus specific primers
were included in the random RT reaction: N165-146
(GCAGGGTAYTTRTACTCATA) previously described
[25] and LRACEF2 (TGAGTCTRTCATCTCACTGG)
at 1 pmol/μl. Ends were repaired and specific sequen-
cing adapters with multiplex identifiers ligated using
the Rapid Library Kit (Roche). The resultant fragments
were purified and size-selected using Ampure XP
(Beckman Coulter) magnetic beads and the libraries
quantified with High Sensitivity DNA chips on a
BioAnalyzer (Agilent).
Libraries were pooled as appropriate in equimolar con-
centrations. Pooled fragments were clonally amplified
using emPCR kits (Roche) and sequenced on the Roche
454 GS FLX + instrument according to the manufac-
turer’s instructions. Each sample was loaded onto 16th
picotitre 454 plate.
Sequence data analysis
Initial assembly of the 454 reads was achieved with Newbler
(V2.6) using the GS de novo assembly software (Roche). All
contigs were exported from the software and were aligned
with a reference genome using Seqman (DNAStar) when-
ever possible. The resulting consensus sequence was subse-
quently used in GS Reference Mapper (Roche) to obtain
further sequence reads from the original raw data. If a suit-
able reference sequence was available, this was used in the
GS Reference Mapper program with the 454 reads to obtain
a consensus sequence without the initial use of the GS de
novo assembly software. Where no suitable genome refer-
ence sequence was available (RV2508) a BLAST search with
the contigs provided evidence for which contigs were viralsequence, using the megablast algorithm on the nucleo-
tide database (http://www.ncbi.nlm.nih.gov/blast/Blast.
cgi?CMD=Web&PAGE_TYPE=BlastHome). Due to the
increased difficulty of mapping reads at the ends of
contigs, it was occasionally necessary to splice the 3′
and/or 5′ UTR sequences from a reference genome se-
quence onto the termini of the contig sequence of inter-
est. Using the spliced consensus sequence in the GS
Reference Mapper program resulted in extra reads be-
ing mapped to the contig resulting in a complete, or al-
most complete genome sequence.Obtaining genomic termini
The lyssavirus genomic termini are extremely con-
served, in particular the first and last 9 nucleotides
have complete complementarity across all lyssaviruses
[1,2,5,22], furthermore the conservation remains stringent
until residue 25 [2]. Previously described panlyssavirus
primers situated at the leader and trailer extremities,
leader: LYS001F (5′ACGCTTAACGAMAAA3′) and
trailer: LYSEND (5′ACGCTTAACAAAWAAA3′) [2]
were used with panlyssavirus primers JW6UNI (5′
CARTTVGCRCACATYTTRT3′) and LgeneFor (5′CT-
CACTGGATMAGRTTRATITACAA3′) respectively to
obtain PCR products which were sequenced dir-
ectly using the PCR primers as described elsewhere
[26].SNP ‘deep sequencing’
Primers flanking the SNP identified for IKOV: RV2508-L
-SNP-F (5′ CTGAAGCTTCGAGACTCTAC 3′) and
RV2508-L-SNP-F (5′ CAGATGGATGACCCTATCAG
3′) were used in a standard RT-PCR reaction, using
high fidelity enzymes in methods described previously
[1]. The amplicons were purified using Ampure XP
(Beckman Coulter) magnetic beads and specific se-
quencing adapters with multiplex identifiers were li-
gated using the Rapid Library Kit (Roche) and purified
using Ampure XP (Beckman Coulter) magnetic beads.
The purified ligated amplicons were size selected and
quantified with High Sensitivity DNA chips on a
BioAnalyzer (Agilent). Amplicons were pooled as ap-
propriate in equimolar concentrations and clonally
amplified using emPCR kits (Roche) and sequenced on
the Roche 454 GS FLX + instrument according to the
manufacturer’s instructions. The RV2508 genome se-
quence was used in the GS Reference Mapper program
with the 454 reads to determine the percentage of reads
present for the SNP.Abbreviations
NGS: Next generation sequencing; BHK: Baby hamster kidney; SNP: Single
nucleotide polymorphism.
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